Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Benoit You"'
Autor:
Tifenn Lharidon, J C Théry, Marie-Ange Mouret Reynier, Philippe Barthélémy, Thomas Filleron, Francesco Del Piano, Marc Debled, Christelle Levy, Monica Arnedos, Alexandra Jacquet, Xavier Tchiknavorian, Florence Dalenc, Alicia Tran-Dien, Anthony Gonçalves, Jean-Marc Ferrero, Fabrice Andre, Mario Campone, Ivan Bièche, Benjamin Verret, Ingrid Garberis, Amélie Lusque, Florence Coussy, Etienne Rouleau, C. Lefeuvre-Plesse, Marie-Paule Sablin, Alice Mege, Marta Jimenez, William Jacot, Benoit You, Thomas Bachelot, Nicolas Isambert, Julien Adam
Publikováno v:
Nature Medicine. 27:250-255
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor recep
Autor:
Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman
Publikováno v:
Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati
Autor:
Fabienne Allias, Benoit You, Touria Hajri, Mojgan Devouassoux-Shisheboran, François Mallet, François Golfier, Jérôme Massardier, Sophie Patrier, Jonathan Lopez, Pierre-Adrien Bolze
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, Elsevier, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, Elsevier, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
International audience; Objective: Using a transcriptional approach on tissue samples, we sought to identify predictive biomarkers of post molar malignant transformation, and of choriocarcinoma chemosensitivity to mono- (methotrexate or actinomycin D
Autor:
Michel Tod, Pierre-Adrien Bolze, Olivier Colomban, Rémi Tod, Benoit You, Michael J. Seckl, Gilles Freyer, R. Osborne, Kathleen Dekeister, Touria Hajri, François Golfier, Jean-Pierre Lotz, Jérôme Massardier
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:15-24
In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a pr
Autor:
Lone Sunde, Kirsty Balanchandran, Minke Frijstein, Georgia Mangili, Sileny Han, Miguel Henriques Abreu, Nataliya Tsip, Anneke M. Westermann, Vilmos Fulop, Franziska Siegenthaler, Michael J. Seckl, Manuela Undurraga, John Coulter, Anne Hills, Angela Salerno, Kamaljit Singh, Lotte Boog, Jacob Korach, Nelleke Ottevanger, Jérôme Massardier, Ulrika Joneborg, Eva Maria Roes, Frédéric Goffin, Luisa Skupin, Fernando Manuel Ribeiro Gomes, Alice Bergamini, Jane Ireson, Benoit You, Catriona Kenneally, Miroslav Korbel, Saša Kadija, Vildana Finci, Isa Niemann, Sarah Delcominette, Antonio Casado, Gloria Marquina, Pierre Adrien Bolze, Grzegorz Szewczyk, François Golfier, Nienke E. van Trommel, Naveed Sarwar, Raffaella Cioffi, Cantù Maria Grazia, Patrick Chien, John Tidy, Christianne A.R. Lok, Gitta Turowski, Yalck K. Eysbouts, Su Harma, Ginette Rosseel, Ulrike Meyer-Hamme, Erika Utracka, Jocelyne Attia, Mehmet Harma, Olesya Solheim, Matthew C Winter, Jean Pierre Lotz, Vesna Kesic, Sophie Patrier, Muge Harma, Janne Kaern, Magdalena Miedzińska, Sinan Ozalp, Eva-Maria Grischke, Amit Mayer, Leigh Bowman, Emelie Wallin, Hind Hamad Elmalik, Leon F.A.G. Massuger
Publikováno v:
European Journal of Cancer, 130, pp. 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
Background and aim Gestational trophoblastic disease (GTD) is a heterogeneous group of disorders characterised by abnormal proliferation of trophoblastic tissue. Since GTD and its malignant sequel gestational trophoblastic neoplasia (GTN) are rare di
Autor:
Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmaña, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy, Constanta Timcheva, Antoaneta Tomova, Andrea Eisen, Karen Gelmon, Julie Lemieux, Fernando Bazan, Hugues Bourgeois, Camille Chakiba, Mohamad Chehimi, Florence Dalenc, Thibault De La Motte Rouge, Jean-Sébastien Frenel, Anthony Gonçalves, Anne Claire Hardy-Bessard, Regine Lamy, Christelle Levy, Alain Lortholary, Audrey Mailliez, Jacques Medioni, Anne Patsouris, Dominique Spaeth, Luis Teixeira, Isabelle Tennevet, Cristian Villanueva, Benoit You, Johannes Ettl, Bernd Gerber, Oliver Hoffmann, Tjoung-Won Park-Simon, Mattea Reinisch, Joke Tio, Pauline Wimberger, Katalin Boer, Alberto Ballestrero, Giampaolo Bianchini, Laura Biganzoli, Roberto Bordonaro, Francesco Cognetti, Michelino De Laurentiis, Sabino De Placido, Valentina Guarneri, Filippo Montemurro, Giuseppe Naso, Armando Santoro, Claudio Zamagni, Seung-Jin Kim, Seigo Nakamura, Yee Soo Chae, Eun Kyung Cho, Kim Jee Hyun, Seock-Ah Im, Keun Seok Lee, Yeon Hee Park, Joo Hyuk Sohn, Tomasz Byrski, Tomasz Huzarski, Bozena Kukielka-Budny, Zbigniew Nowecki, Renata Szoszkiewicz, Rafal Tarnawski, Viktoria Dvornichenko, Fedor Moiseenko, Guzel Mukhametshina, Elena Poddubskaya, Ekaterina Popova, Anna Tarasova, Anna Vats, Bárbara Adamo, Raquel Andrés Conejero, Antonio Antón Torres, Judith Balmaña Gelpi, Nieves Díaz Fernández, Alejandro Falcón González, Juan Garcia, Isabel Lorenzo-Lorenzo, Fernando Moreno Antón, Marta Santisteban, Agostina Stradella, Chiun-Sheng Huang, Sercan Aksoy, Cagatay Arslan, Mehmet Artac, Adnan Aydiner, Ozgur Ozyilkan, Emel Sezer, Anne Armstrong, Sophie Barrett, Annabel Borley, Zoe Kemp, Caroline Michie, Mukesh Mukesh, Timothy Perren, Angela Swampillai, Tammy Young
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Background In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-nega
Autor:
Fanny Valleix, Tetsuo Taguchi, Benoit You, Yutaro Kaneko, Thomas Podoll, Naoto Hirota, Nicolas Isambert, Kei Ohnuma, Ryo Hatano, Gérard Zalcman, Nam H. Dang, Eric Angevin, Véronique Trillet-Lenoir, Seiichi Takao, Yoshimi Umezawa, Taketo Yamada, Chikao Morimoto, Osamu Hosono, Satoshi Iwata, Jérôme Alexandre
Publikováno v:
Biomarker Research
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ce65814344ffa433e56209cace7b82
https://doi.org/10.21203/rs.3.rs-126614/v1
https://doi.org/10.21203/rs.3.rs-126614/v1
Autor:
M Puglisi, Nicoletta Colombo, Robert L. Coleman, Cagatay Taskiran, Ana Oaknin, Linda R. Duska, Kosei Hasegawa, M Raza Mirza, C Martin, David Cibula, Jacob Korach, Benoit You, Angélica Nogueira-Rodrigues, Y Xiang, Stephen Michael Keefe, Leslie M Randall, Jalid Sehouli, Melissa Christiaens, Sandro Pignata, Domenica Lorusso
Publikováno v:
Poster.
Background High-risk locally advanced cervical cancer (CC) has a poor prognosis, and >50% of patients recur in 2 years. Concurrent chemoradiotherapy (CRT) may enhance the immunostimulatory activity of the PD-1 inhibitor pembrolizumab. After KEYNOTE-1
Autor:
Jérôme Meunier, Florence Joly, Joël Lachuer, E. Malaurie, Marie-Christine Kaminsky, Dominique Berton-Rigaud, Jérôme Alexandre, Gaëtan de Rauglaudre, Coraline Dubot, Michel Tod, Patrick Robelin, Olivier Colomban, Alexandra Leary, Gwenael Ferron, Isabelle Ray-Coquard, Alain Lortholary, Annick Chevalier-Place, Salima Hamizi, Benoit You, N. Raban, Pierre Combe
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, Elsevier, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, Elsevier, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
International audience; Objective: MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemothera
Publikováno v:
Cancer Research. 78:1873-1882
Antimitograms are prototype in vitro tests for evaluating chemotherapeutic efficacy using patient-derived primary cancer cells. These tests might help optimize treatment from a pharmacodynamic standpoint by guiding treatment selection. However, they